12.2.2022

ISR Vaccine AB signs contract with Oncovir Inc for the adjuvant to the vaccine

ISR Vaccine AB has today signed a contract with the US company Oncovir Inc. for the rights to

use their adjuvant Hiltonol  in the SARS-CoV-2 vaccine, and their assistance to carry out tech

transfer to CMO company for large scale GMP production.

”The well-used adjuvant from Oncovir fits nicely with our vaccine formulation, which together

with full length spike mimics the natural SARS-CoV-2 infection with induction of antibodies and

a strong T cell response. In our preclinical studies we have been very impressed by the

stimulatory direction of the adjuvant and with the lack of side effects in the doses used in

respiratory tract administration”, comments Ola Winqvist, CEO ISR.

With the signing with Oncovir, ISR has secured another key component and their large scale

production in preparation for the phase III clinical trial and for the market phase. The nasal

inhalation vaccination uses natural spike protein, the addition of an adjuvant in a formulation

presented for the immune system in the respiratory tracts which induces a strong local mucosal

immune response.

“We see excellent potential with the combination of Poly-ICLC and ISRs spike protein to

address the ongoing SARS-CoV2 pandemic. ISR has a great team, and we are looking

forward to this collaboration”, comment Andres M. Salazar, CEO of Oncovir

 

For further information, please contact:

Ola Winqvist

CEO, ISR Immune System Regulation Holding AB (publ)

E-post: ola.winqvist@israb.se

Phone: +46 (0)70 5427939

About ISR Immune System Regulation Holding AB (publ)

ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses

on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune

regulating pharmaceutics. Mangold is the company’s Certified Adviser,

and can be reached on phone +46 (0)8-46380 00.

www.israb.se

This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying

with EU’s Market Abuse Regulation (MAR), and the Market Abuse Act

About Oncovir

Oncovir, Inc is a Virginia, USA based pharmaceutical corporation dedicated to the development of nucleic-acidbased

clinical therapies for cancer, infectious, immune, and degenerative disorders. We promote Hiltonol  (Poly-

ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity.